A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Patients aged over 18 years old.
• Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
• Patients has received Trastuzumab Deruxtecan
• Available medical history.
Locations
Other Locations
Russian Federation
Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation
RECRUITING
Moscow
Contact Information
Primary
Elena Artamonova
tatiana.titovadoc@gmail.com
+7 (499) 444-24-24
Time Frame
Start Date: 2025-12
Estimated Completion Date: 2026-05
Participants
Target number of participants: 60
Treatments
Experimental: Patients with unresectable or metastatic HER2+ BC who have received one or more cycles T-DXd
Related Therapeutic Areas
Sponsors
Leads: Blokhin's Russian Cancer Research Center